PharmAbcine
Korea - DaejeonBiotechnology
Focus: PharmAbcine is a Korea-based antibody-focused biotechnology company developing targeted therapies in oncology and ophthalmology. The company operates as a pre-revenue stage biotech with a clinical-stage pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About PharmAbcine
AI assessmentNot HiringNo open roles listed right now. Follow PharmAbcine to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TTAC-0001 and pembrolizumab combination
Triple Negative Breast CancerClinical Trials (1)
NCT03720431TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
Phase 1Help build intelligence for PharmAbcine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.